VPT:CC - Ventripoint and Lishman Global Sign Non-binding Term Sheet Defining License for VMS+ Technology
(TheNewswire)
Toronto, Ontario – TheNewswire - July 11, 2025 –Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the“ Corporation ” ) , ( TSXV:VPT) is pleased to announce that it has signed a non-binding termsheet with Lishman Global Inc. outlining the exclusive ,non-transferable license of Ventripoint technology for use withinLishman’s echocardiography image platform in the People’s Republicof China including the Special Administrative Regions of Hong Kong andMacao (the “Territory”).
Previously, Lishman’s Chinese subsidiary had received CFDA approval and a Certificate of Production(CoP) from the CFDA in the People’s Republic of China for the VMS+ product used foranalysis of the right ventricle (RV) only of the heart. The subsidiary has a GMP certifiedmanufacturing facility in China that is able to produce at a scalecapable of addressing the Chinese market.
Upon execution , the new license will enableLishman and its subsidiaries to fully integrateVMS+ 4.0 within its cart-based and hybrid echocardiography platformsand to market the technology within the Territory. The final licensewill specify annual minimum volumes once CFDA approval has beensecured. Lishman has placed a purchase order for VMS+ componentsneeded to support the manufacture of systems sufficient to supportvalidation of the product and submission to CFDA. Lishman hascommitted to an investment into Ventripoint.
“We appreciate the ongoing commitment of our Chinesepartners to VMS+,” stated Hugh MacNaught, President and CEO. “Heart disease remains the number one healthcare issue in Chinawith nearly twice the rate of hospital admissions for cardiovascularconditions than in North America. China has a higher rate of use ofechocardiograms than in North America and is expected to benefit fromboth the performance improvements inherent to VMS+ that enable greateraccuracy of echo studies and the ability of the system to work withsparse data that should reduce the number of repeat studies. Upon CFDAapproval all 32,000 hospitals in China and its territories will gainawareness of a 2D echocardiography system that generates volumetricresults with similar levels of accuracy to cMRI.”
“We are looking forward to working closely withVentripoint to integrate VMS+ within our platforms, secure CFDAapproval, and actively market our solution to the Chinese clinicalcommunity” stated Paul Gibson, CTO of Lishman.
Pre-marketing efforts are underway in the Chinesemarket with the objective of establishing a presence within each ofthe 22 provinces plus the Special Administrative Regions within thecountry. There are over 2,500 Tier 1 hospitals and a total of 32,000hospitals, with over 1,000 new hospitals currently underconstruction.
About Lishman Global.
Lishman Global was establish in 2012 to assistcompanies to safely enter the Chinese Market. Our partnership modelallows foreign companies to navigate the complex network of regulatoryapprovals and multi-level distribution channels common in the Chinesemedical device market.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary knowledge-based reconstruction technology, which is theresult of a decade of development and provides accurate volumetriccardiac measurements equivalent to MRI. This affordable, gold-standardalternative allows cardiologists greater confidence in the managementof their patients. Providing better care to patients serves as aspringboard and basic standard for all of Ventripoint's products thatguide our future developments. In addition, VMS+ is versatile and canbe used with all ultrasound systems from any vendor supported byregulatory market approvals in the U.S., Europe and Canada.
For further information, pleasecontact:
Hugh MacNaught
hmacnaught@ventripoint.com
604-671-4201
Neither the TSX Venture Exchange norits Regulation Services Provider (as that term is defined in thepolicies of the TSX Venture Exchange) accepts responsibility for theadequacy or accuracy of this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Corporation.Although the Corporation believes that the expectations andassumptions on which such forward-looking statements and informationare based are reasonable, undue reliance should not be placed on theforward-looking statements and information because the Corporation cangive no assurance that they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Corporation'smost recent annual management's discussion and analysis that isavailable on the Corporation's profile on SEDAR+ at www.sedarplus.ca. Readersare cautioned that the foregoing list of factors is not exhaustive.The forward-looking statements included in this news release areexpressly qualified by this cautionary statement. The forward-lookingstatements and information contained in this news release are made asof the date hereof and the Corporation undertakes no obligation toupdate publicly or revise any forward-looking statements orinformation, whether as a result of new information, future events orotherwise, unless so required by applicable securities laws.
Copyright (c) 2025 TheNewswire - All rights reserved.